Endonovo Therapeutics (OTC:ENDV) said today it has settled a lawsuit between it and Kodiak Capital Group over a contemplated equity investment by the firm in Endovo. Los Angeles-based Endonovo said that the groups had reached a settlement agreement and dismissed all complaints and cross-complaints from the contemplated investments. As part of the settlement, Kodiak is returning […]
Endonovo Therapeutics
Anonymous strategic investor puts another $5m into Endonovo’s Immunotronics
Endonovo Therapeutics (OTC:ENDV) said this week that it inked a $5 million deal with an anonymous strategic investor aimed at retiring its convertible debt, launching pre-clinical studies of its Immunotronics platform and uplisting its shares. The Los Angeles-based company, which is developing technology it calls “Immunotronics” to stimulate liver regeneration and treat inflammatory conditions, said it […]
Endonovo Therapeutics raises $10 million
Endonovo Therapeutics (OTC:ENDV) said today that it landed a $10 million funding agreement with an institutional investor. The funding consists of $1 million in convertible notes, with $600,000 already received and $400,000 to be received upon SEC registration approval, and up to $9 million through a securities purchase agreement after 30 days from its SEC registration date. […]
Rio Grande Neurosciences backs out of $22m Endonovo deal
Rio Grande Neurosciences last week backed out of its pending acquisition by Endonovo Therapeutics (OTC:ENDV), after seeking to renegotiate the terms of the $22 million deal, Endonovo said. Steven Gluckstern, chairman & CEO of Santa Fe-based Rio Grande, dissolved a binding letter of intent August 19 “following its request to renegotiate the terms of the binding LOI, […]
Endonovo Therapeutics raises $10m for Rio Grande buy
Endonovo Therapeutics (OTC:ENDV) said today that it raised $10 million it plans to use to fund the $22 million acquisition of Rio Grande Neurosciences. The backing from an unnamed institutional investor consists of $1 million in convertible notes and another $9 million in a securities purchase agreement, Los Angeles-based Endonovo said. The company said it’s received $400,000 […]
Endonovo Therapeutics inks $22m deal for Rio Grande Neurosciences
Endonovo Therapeutics (OTC:ENDV) said today that it agreed to pay $21.5 million to acquire Rio Grande Neurosciences and its non-invasive devices for treating brain disorders. The cash-and-stock deal calls for Endonovo to put up $1.5 million in cash, another $15 million in ENDV shares and $5 million worth of warrants. The companies signed a binding letter […]
Endonovo Therapeutics lands $10M
Endonovo Therapeutics said it raised $10 million in a private placement with an unnamed investor.
The Woodland Hills, Calif.-based company is developing non-invasive, electromagnetic therapies with time-varying electromagnetic fields to regenerate tissue and organs that have been damaged by age or disease.
